维拉治疗 VERA
$29.79 −$0.36 (-1.18%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $30.37 +1.96%
开盘$30.48
昨收$30.14
当日区间$28.04 – $30.84
成交量2.08M
市值$2.15B
市盈率（TTM）–
股息率–
VERA 相关新闻
匹配 Vera Therapeutics 或代码 VERA 的头条新闻，按最新排序。
- Is NVIDIA (NVDA.US) facing renewed resistance as its stock price hits new highs? Amid surging demand for both GPUs and Vera CPUs, a director has cashed out $300 million in a major sell-off.
- NVIDIA's stock hits a new high but faces resistance again? As demand for GPUs and Vera CPUs surges on two fronts, a Director has cashed out $300 million. 正面
- Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Maintains Target Price $34
- A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $90
- TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $78
- Takeda Pharmaceutical: Regarding the U.S. Food and Drug Administration (FDA) approval of MIMRYLO (rusfertide), which has the potential to usher in a paradigm shift in the treatment of polycythemia vera. 正面
- Takeda Pharmaceutical: Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera 正面
- J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $76 负面
- Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
- HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Lowers Price Target to $90
- H.C. Wainwright Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 负面
- A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $34 to $100
- Wedbush Maintains Vera Therapeutics(VERA.US) With Hold Rating, Cuts Target Price to $43 负面
- LifeSci Capital Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $90
- Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $91
暂无评论——快来第一个聊聊 VERA。
登录后参与讨论。